DSM & Evonik Collaborate on Marine Algae for Animal Nutrition & Aquaculture

f3d88092-1081-42ee-b8db-9f2c864da629articleimage.jpg

08 Mar 2017 --- Royal DSM and Evonik have announced plans to establish a joint venture producing omega-3 fatty acid products from natural marine algae for the animal nutrition and aquaculture markets. The innovation will enable the sustainable production of omega-3 fatty acids for animal nutrition without using fish oil from wild caught fish.

“Our products will initially target the salmon aquaculture and pet food markets,”

Herman Betten, Global Director External Affairs, Royal DSM, explained to NutritionInsight.

“With currently 17% of the world’s wild caught fish being used to produce fish oil for aquaculture, we believe this is unsustainable.”

“By producing omega 3 with EPA and DHA from algae, we will enable the aquaculture industry to grow sustainably,” notes Betten.

The companies have said that their highly concentrated algal oil is a high value and pure source that will enable the animal nutrition industry to keep up with the increasing demand for these two essential omega-3 fatty acids without endangering fish stocks.

They add that this will contribute to healthy animal nutrition as well as to the ecological balance and biodiversity of the oceans - something they regard as a breakthrough in the industry.

Betten added: “DSM and Evonik are building a facility in response to the anticipated growth from the aquaculture industry for omega-3 with EPA and DHA, with fish oil being a finite resource.”

The alternative omega-3 source is the first to offer both EPA and DHA and will be aimed at initial applications in salmon aquaculture and pet food.

Complimentary Offerings

The companies state that the successful product and process development was only possible thanks to the complementary competencies that Evonik and DSM bring to the collaboration.

DSM has expertise in the cultivation of marine organisms including algae and long-established biotechnology capabilities in development and operations, whilst Evonik's focus has been on developing industrial biotechnology processes and operating competitively large-scale manufacturing sites for fermentative amino acids.

Joint Development

DSM Nutritional Products and Evonik Nutrition & Care will each hold a 50% share in the joint venture and co-own the production facility, which will be built at an existing site of Evonik and is expected to come on stream in 2019. The joint venture plans to invest around US$ 200 million in the facility (USD 100 million by each party over circa 2 years).

The company has set its goals high, with Betten explaining that, “We are initially covering 15% of the current annual demand for EPA and DHA from the salmon aquaculture industry.”

The set-up of the joint venture, to be named Veramaris and headquartered in The Netherlands, will be finalized subject to regulatory approvals and other customary closing conditions.

The joint venture follows the joint development agreement, signed in July 2015. Under this agreement, Evonik and DSM have jointly worked on the development of products and the manufacturing process and explored opportunities for commercialization.

Both companies achieved positive results in the development of the product while extensively working with the entire value chain, including fish feed producers, fish farmers and retailers.

Under the joint development agreement, DSM and Evonik have successfully produced pilot-scale quantities of the algal oil at DSM’s production facility in Kingstree, South Carolina (United States).

Customers will be able to receive sizeable quantities of the product for market development while the construction of the new manufacturing plant is underway.

Sustainability in the Aquaculture industry

The algal oil from DSM and Evonik means that the vision of salmon farming without using fish-based resources is – for the first time – becoming realistic. By replacing fish oil in salmon feed with this EPA and DHA rich alternative, the fish-in-fish-out ratio could be reduced significantly.

The two companies state that this alternative will enable the aquaculture industry to continue to grow sustainably.

Worldwide fish oil production is approximately one million metric tons per year. Most of the fish oil is used in aquaculture, mainly for fat-rich fish species, such as salmon. The limited wild fish stocks restrict the amount of fish oil available and thus the growth of the aquaculture industry.

Currently, the industry uses about 75% of the annual production of fish oil.

Growth in the Pet Food Market

Just like humans, animals also need their daily intake of essential, long-chain polyunsaturated fatty acids in their diet to ensure healthy growth.

Until now, these fatty acids have been added to aquaculture feed and pet food almost exclusively from marine sources such as fish oil and fishmeal.

As the new algal oil can be applied in feed production in the same way as fish oil, it can easily be introduced by feed and pet food producers, offering a sustainable non-fish alternative.

The omega 3 pet food market is growing too. According to Innova Market Insights, launches of pet foods featuring omega 3 rose 2.5% from 2015 to 2015, indicating that there is potential for the companies to really dominate this area.

DSM and Evonik are also pursuing applications of their algal oil for other aquatic and terrestrial animal species.

by Hannah Gardiner

To get in touch with this editor, email hannah@cnsmedia.com

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Packaging & Technology News

Tetra Pak: Plant-based, water, liquid nutrition and cheese categories set for growth

18 Oct 2018 --- Population growth, enhanced connectivity and demand for sustainability are all key market dynamics motivating Tetra Pak’s trend predictions. At the company’s recent event, Inside Tetra Pak, held in Lund, Sweden, the company offered insights into how such dynamics are shaping interest in plant-based beverages, water, cheese and food supplement nutrition. These trends will continue to grow, the company noted, and Tetra Pak can offer ideal packaging and processing solutions to support NPD.

Health & Nutrition News

Ashwagandha: Rooted in tradition, set for sky-high NPD growth 

18 Oct 2018 --- Boosted by growing consumer demand for natural remedies to fight the daily stresses of modern life, the adaptogenic herb ashwagandha is seeing an impressive uptake in usage. Innova Market Insights data has shown an increase of 48 percent in the number of food and beverage launches globally in 2018 (year to date) relative to 2015, and the adaptogenic herb’s market potential has not gone unnoticed by suppliers, with both Arjuna Natural and Sabinsa announcing the launch of ashwagandha ingredients this autumn.

Health & Nutrition News

Brexit’s impact on the sugar tax: Greater reductions in coronary heart disease mortality rates

15 Oct 2018 --- The British “sugar tax” will continue to reduce coronary heart disease deaths (CHD), regardless of whether the terms of the UK's impending exit from the EU are “soft” or “hard,” finds a study published in Public Health Nutrition. The researchers identified that reductions in CHD mortality were 4 percent and 8 percent greater under “soft” and “hard” Brexit scenarios, respectively. 

Food Ingredients News

Astaxanthin could help stave off sarcopenia in seniors

10 Oct 2018 --- A formulation containing AstaReal natural astaxanthin can provide a 40 percent increase in endurance and significantly improves muscle function in sarcopenia sufferers. This is according to a study by AstaMed investigating muscle loss and functional decline in older adults with the disease. Sarcopenia affects nearly a quarter of adults older than 60. Researchers published the findings in The Journal of Cachexia, Sarcopenia and Muscle on the effectiveness of a new medical protocol to improve muscular function.

Health & Nutrition News

HMO expansion: Jennewein Biotechnologie to strengthen portfolio with Arthus Mineralsprings facility buy

09 0ct 2018 --- Jennewein Biotechnologie is to expand its production of human milk oligosaccharides (HMO) from its current portfolio of two products to include five more. The expansion is facilitated through the company's acquisition of the former facilities of Arthus Mineralsprings in Bad Hönningen, Germany. Jennewein plans to build a new integrated fermentation and recovery plant for the production of HMOs.

More Articles
URL : http://www.nutritioninsight.com:80/news/dsm-evonik-collaborate-on-marine-algae-for-animal-nutrition-aquaculture.html